Inhalation Sciences announces outcome of exercise of warrants of series TO 1

On 3 June 2022, the period for exercising warrants of series TO 1 for subscription of shares in Inhalation Sciences Sweden AB (publ) (“the Company”) ended. No warrants were exercised.

Each warrant of series TO 1 entitled to subscribe for one (1) new share in the Company at a subscription price per share of SEK 10.00 during the period from and including 23 May 2022 to and including 3 June 2022. No warrants were exercised and thus no new shares will be issued with support of the warrants of series TO 1. All warrants of series TO 1 will be cleared from the holder’s VP account or custody account.

For more information on Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt^® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.